BioVie (BIVI) Expected to Announce Quarterly Earnings on Tuesday

BioVie (NASDAQ:BIVI) is expected to issue its Q2 2026 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, February 9, 2026 at 4:00 PM ET.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.19).

BioVie Stock Up 8.8%

NASDAQ BIVI opened at $1.24 on Tuesday. The company has a 50-day simple moving average of $1.34 and a two-hundred day simple moving average of $2.10. BioVie has a 12-month low of $1.10 and a 12-month high of $20.40. The firm has a market cap of $9.35 million, a price-to-earnings ratio of -0.18 and a beta of 0.36.

Institutional Trading of BioVie

Several large investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in BioVie during the 2nd quarter valued at about $40,000. NewEdge Advisors LLC increased its stake in shares of BioVie by 283.7% during the first quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock valued at $53,000 after buying an additional 40,000 shares during the period. Jane Street Group LLC bought a new position in shares of BioVie during the second quarter valued at approximately $57,000. Two Sigma Investments LP purchased a new stake in BioVie in the third quarter worth $62,000. Finally, Squarepoint Ops LLC bought a new stake in BioVie in the third quarter valued at $63,000. 4.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

About BioVie

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.